Core Viewpoint - Tianfeng Securities issued a report on August 14, giving Dongmu Co., Ltd. (600114.SH, latest price: 26.05 yuan) a "buy" rating based on strong growth in MIM and continuous improvement in profitability [2] Group 1: MIM Growth and Applications - MIM is experiencing strong growth, which is complemented by cost reduction and efficiency enhancement, leading to sustained improvement in profitability [2] - The three major platforms are collaborating effectively, with MIM enabling diverse application scenarios such as foldable screen hinges, AI, and robotics [2] Group 2: P&S and SMC Opportunities - In the P&S segment, hybrid vehicles maintain core scenarios while robotic gears are opening new opportunities [2] - The SMC segment is seeing growth potential driven by demand for automotive applications and AI computing power [2]

The wizards have arrived 🧙‍♂️ ✨$MIM @mimcoinbtc is live ⤵️https://t.co/P3aaAEjAyJ*Geographic restrictions apply https://t.co/JjzfNIJ7PF ...

🔥 08.08 Daily Top 5 Gainers on #AscendEX 🔥🏅 $MIM +154.16%🥈 $DESCI +152.63%🥉 $A2Z +74.13%🎖 $NEIROS +46.86%🎖 $URANUS +44.78%🚀 Time to ride the wave?👇 Trade now and catch the next big move!🔗 https://t.co/c6hC9OD49a👀 Want more insider updates?👇 Join the community!🔗 https://t.co/17FuV2jtg1🚀 AscendEX: Ascend in Trading, Lead in Memes.#AscendEX #Crypto #Memecoin #TopGainers #TradeNow ...

⏰ Price Alert!🚀 $MIM has surged +154.16% on AscendEX in the last 24 hours!📈 The market is moving! Don’t miss out!🔗 Trade Now👉 https://t.co/c6hC9ODBYI👥 Join our official group👉 https://t.co/17FuV2k15z🔥 Join AscendEX: Upgrade your trading experience.#AscendEX #Crypto #PriceAlert #Trading ...

GE HealthCare Technologies (GEHC) Q2 2025 Earnings Call July 30, 2025 08:30 AM ET Company ParticipantsCarolynne Borders - Chief Investor Relations OfficerPeter Arduini - President & CEOJames Saccaro - VP & CFOVijay Kumar - Senior MDJoanne Wuensch. - Managing DirectorDavid Roman - Managing DirectorMatt Taylor - Managing DirectorRick Wise - Managing Director - Medical Technology & SuppliesConference Call ParticipantsLawrence Biegelsen - Senior Medical Device Equity Research AnalystRobert Marcus - Senior Analy ...

Investment Rating - The investment rating for the company is maintained as "Buy" [8] Core Views - The company has shown robust performance with a revenue increase of 33.20% year-on-year in 2024, reaching 5.143 billion RMB, and a net profit growth of 100.59% to 397 million RMB [1][2] - The company is focusing on three major material technology platforms: Powder Metallurgy (P&S), Soft Magnetic Composite (SMC), and Metal Injection Molding (MIM), targeting sectors such as new energy and high-end manufacturing [4] - The company is expected to maintain stable earnings with projected net profits of 487 million RMB, 585 million RMB, and 626 million RMB for 2025, 2026, and 2027 respectively [5] Revenue and Profitability - In Q1 2025, the company achieved a revenue of 1.459 billion RMB, a year-on-year increase of 32.41%, while the gross margin was 21.95%, showing a slight decline [3] - The MIM business has seen significant growth, with a revenue increase of 92.19% year-on-year, driven by the recovery in the smartphone market [2][3] Financial Projections - The company forecasts a revenue of 5.737 billion RMB for 2025, with a year-on-year growth of 11.56% [7] - The expected earnings per share (EPS) for 2025 is projected at 0.79 RMB, with a price-to-earnings (PE) ratio of 27.7 times, leading to a target price of 21.88 RMB [5][9]